Evolution and outcomes of sentinel lymph node mapping in vulvar cancer.
lymph nodes
melanoma
sentinel lymph node
surgical procedures, operative
vulvar and vaginal cancer
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
17
09
2019
revised:
18
12
2019
accepted:
26
12
2019
pubmed:
23
2
2020
medline:
25
8
2020
entrez:
21
2
2020
Statut:
ppublish
Résumé
To characterize our institutional experience with sentinel lymph node (SLN) biopsy in patients with vulvar cancer. We describe the oncologic outcomes of these patients and the utilization of SLN detection techniques over time. A retrospective analysis of all patients who underwent inguinofemoral SLN biopsy as part of their treatment for vulvar cancer at Memorial Sloan Kettering Cancer Center from January 1, 2000 to April 1, 2019. Patients were included in this analysis if they underwent inguinofemoral SLN biopsy for vulvar cancer, irrespective of presenting factors such as histology, tumor size or laterality. An "at-risk groin" was defined as either the right or left groin for which SLN biopsy of inguinofemoral lymph nodes was performed. A total of 160 patients were included in our analysis, representing 265 at-risk groins. 114 patients had squamous cell histology representing 195 at-risk groins. Of the 169 negative groins in patients with squamous cell carcinoma, the 2 year isolated groin recurrence rate was 1.2%. SLN detection rate, irrespective of modality, was 96.2%. Technetium-99 (TC-99) + blue dye detected SLNs in 91.8% of groins; TC-99 + indocyanine green detected SLNs in 100% of groins (p SLN mapping in vulvar cancer is reliable and oncologically effective. The utilization of indocyanine green for mapping has increased over the past decade and is associated with high rates of SLN detection.
Identifiants
pubmed: 32075896
pii: ijgc-2019-000936
doi: 10.1136/ijgc-2019-000936
pmc: PMC7477673
mid: NIHMS1614388
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-386Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: NRA-R reports grants from Stryker/Novadaq, grants from Olympus, grants from GRAIL, outside the submitted work. DSC reports personal fees from Bovie Medical Co, personal fees from Verthermia Inc. (now Apyx Medical Corp), personal fees from C Surgeries, other from Intuitive Surgical, Inc, other from TransEnterix, Inc, personal fees from Biom 'Up, outside the submitted work. EJ is a consultant for Intuitive Surgical and Covidien, outside the submitted work. ML is a consultant for Intuitive Surgical, outside the submitted work.
Références
Br J Cancer. 2014 Jun 10;110(12):2837-46
pubmed: 24867697
Lancet Oncol. 2010 Jul;11(7):646-52
pubmed: 20537946
J Am Coll Surg. 2003 Mar;196(3):442-50
pubmed: 12648697
Gynecol Oncol. 2016 Jan;140(1):8-14
pubmed: 26428940
Am J Obstet Gynecol. 1979 Apr 1;133(7):825-32
pubmed: 434024
J Clin Oncol. 2012 Nov 1;30(31):3786-91
pubmed: 22753905
Clin Obstet Gynecol. 2005 Dec;48(4):862-8
pubmed: 16286832
Gynecol Oncol. 2011 Feb;120(2):291-5
pubmed: 21056907
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gynecol Oncol. 2001 Aug;82(2):329-32
pubmed: 11531288
J Vis Exp. 2010 Oct 20;(44):
pubmed: 21048667
Int J Gynecol Cancer. 2017 May;27(4):805-812
pubmed: 28399034
Gynecol Oncol. 2007 Mar;104(3):636-41
pubmed: 17095080